Pula General Hospital Ospedale Generale di Pola

At Pula General Hospital Ospedale Generale di Pola, investigators are evaluating a novel lipid‑lowering therapy to reduce the incidence of major adverse cardiovascular events in high‑risk patients as part of primary prevention efforts.

• Evaluation of inclisiran for ASCVD primary prevention
• Cardiovascular safety monitoring in immunotherapy combination trials
• Long‑term outcome assessment in patients with elevated cardiovascular risk

The department contributes several of the nine ongoing trials, with a team of seven investigators guiding the research.

The oncology division is testing cutting‑edge immunotherapies and biosimilars to improve outcomes for individuals with metastatic non‑small cell lung cancer, focusing on response rates and safety profiles.

• Comparison of new checkpoint inhibitor combinations in NSCLC
• Biosimilar equivalence study with Keytruda (CT‑P51)
• Second‑line acasunlimab plus pembrolizumab versus standard docetaxel
• Fixed‑dose combination safety of tiragolumab and atezolizumab

Across the nine trials, lung cancer remains a central focus, leveraging the expertise of seven clinical investigators.

A dedicated study is examining a new agent for agitation in Alzheimer’s‑type dementia, aiming to provide a safer option that eases behavioral disturbances while maintaining tolerability.

• Safety and tolerability assessment of AVP‑786
• Behavioral outcome measures in dementia patients
• Quality‑of‑life impact evaluation for caregivers

This trial reflects the department’s commitment to improving neurological care alongside its oncology and cardiovascular programs.

Researchers are investigating an investigational compound that promotes weight loss and enhances glycemic control in adults with obesity and type 2 diabetes, with the goal of lowering cardiovascular risk.

• Effect of NNC0487‑0111 on body weight reduction
• Impact on glucose metabolism and HbA1c levels
• Safety and tolerability profile in overweight participants

These metabolic studies complement the cardiovascular prevention initiatives underway at the hospital.